New approval for Hofseth BioCare's salmon oil is a breakthrough for the company.
Hofseth BioCare has achieved NDI (New Dietary Ingredient) status from the US Food and Drug Administration (FDA) for the CalGo and OmeGo supplements extracted from Norwegian Atlantic salmon.
Hofseth BioCare is now part of an exclusive list of companies that have achieved NDI status with the FDA for their new dietary ingredients in these two supplements.
- It is tough to enter the world market for diet and health products. Hofseth BioCare from Ålesund with a factory in Midsund is a small challenger in a giant market for health and diet products. This is a unique recognition from the US health authorities, there are only 40-50 products that receive such approval every year, says CEO of Hofseth BioCare, Roger Hofseth.
Roger Hofseth has always believed that the HBC hydrolysis technology - extracting the entire nutritional content of Norwegian Atlantic salmon – ultimately will be recognized by world markets.
– Over the last 15 years, Hofseth BioCare has invested a substantial amount of capital to have the ingredients examined and documented. We have developed a robust portfolio of patents and trademarks to protect our property rights. Now it seems like my big dream is about to come true, and it makes me incredibly happy. We are in the process of building something big from small Ålesund, says Roger Hofseth.
According to Hofseth BioCare's partner and distributor KGK Science, the HBC products will achieve a completely different attention in the markets around the world with this approval.
- The FDA decision helps Hofseth BioCare into the global market as many countries outside the US look for certificates that the dietary supplement has been approved by the US health authorities, says Najla Gutherie, president and CEO of KGK Science.